Overview Dividends

(BNTX) BioNTech SE - Ratings and Ratios

Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US09075V1026

Oncology Vaccines,Checkpoint Antibodies,MRNA Therapies,Cellular Immunotherapies

BNTX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -37.47%
EPS Trend (3Y Correlation): -53.8%

BNTX Revenue

Revenue Growth (3Y CAGR): -60.95%
Revenue Trend (3Y Correlation): -56.3%

Description: BNTX BioNTech SE October 14, 2025

BioNTech SE (NASDAQ:BNTX) is a German biotechnology firm focused on developing mRNA-based immunotherapies for cancer and infectious diseases. Its pipeline includes more than 20 candidates across all clinical phases, notably BNT111 (Phase 2 melanoma), BNT113 (Phase 2 head-and-neck squamous cell carcinoma), BNT116 (Phase 1 non-small cell lung cancer), and the multi-indication BNT122/RO7198457 (Phase 2 adjuvant urothelial carcinoma, colorectal, pancreatic and advanced melanoma). The company also advances late-stage assets such as BNT311/GEN1046 (Phase 3 solid tumors) and BNT327 (spanning Phase 1-3 trials for small-cell lung cancer, TNBC, neuroendocrine neoplasms, and hepatocellular carcinoma).

Key recent metrics: as of Q2 2024, BioNTech reported €2.9 billion in revenue, driven primarily by its COVID-19 vaccine partnership with Pfizer, while cash and equivalents stood at €4.1 billion, providing a runway of over three years at current burn rates. The mRNA platform’s scalability and the broader biotech sector’s 12-month forward-looking P/E median of ~30× underscore both high growth potential and valuation pressure. A material driver of future earnings is the ability to leverage the existing mRNA manufacturing network for oncology candidates, which could reduce cost-of-goods-sold (COGS) by up to 20 % relative to early-stage trials.

For a deeper quantitative assessment, the ValueRay platform offers a granular view of BNTX’s risk-adjusted upside.

BNTX Stock Overview

Market Cap in USD	24,667m
Sub-Industry	Biotechnology
IPO / Inception	2019-10-10

BNTX Stock Ratings

Growth Rating	-39.6%
Fundamental	13.8%
Dividend Rating	1.0%
Return 12m vs S&P 500	-21.6%
Analyst Rating	4.38 of 5

BNTX Dividends

Currently no dividends paid

BNTX Growth Ratios

Growth Correlation 3m	-42.8%
Growth Correlation 12m	-43.2%
Growth Correlation 5y	-56.9%
CAGR 5y	-8.40%
CAGR/Max DD 3y (Calmar Ratio)	-0.15
CAGR/Mean DD 3y (Pain Ratio)	-0.21
Sharpe Ratio 12m	-1.05
Alpha	-31.74
Beta	1.462
Volatility	34.92%
Current Volume	341.1k
Average Volume 20d	604.4k
Stop Loss	102.8 (-3.1%)
Signal	0.01

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-347.4m TTM) > 0 and > 6% of Revenue (6% = 172.7m TTM)

FCFTA -0.12 (>2.0%) and ΔFCFTA -22.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 489.1% (prev 588.9%; Δ -99.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.08 (>3.0%) and CFO -1.77b <= Net Income -347.4m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (241.6m) change vs 12m ago 1.64% (target <= -2.0% for YES)

Gross Margin 79.84% (prev 64.42%; Δ 15.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 13.12% (prev 12.11%; Δ 1.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -9.21 (EBITDA TTM -227.6m / Interest Expense TTM 52.7m) >= 6 (WARN >= 3)

Altman Z'' 12.60

(A) 0.65 = (Total Current Assets 15.93b - Total Current Liabilities 1.85b) / Total Assets 21.64b

(B) 0.85 = Retained Earnings (Balance) 18.30b / Total Assets 21.64b

warn (B) unusual magnitude: 0.85 — check mapping/units

(D) 5.45 = Book Value of Equity 17.07b / Total Liabilities 3.13b

Total Rating: 12.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 13.78

1. Piotroski 1.0pt = -4.0

2. FCF Yield -34.18% = -5.0

3. FCF Margin -88.12% = -7.50

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda 43.94 = -2.50

6. ROIC - WACC (= -13.69)% = -12.50

7. RoE -1.83% = -0.30

8. Rev. Trend -56.29% = -4.22

9. EPS Trend -53.83% = -2.69

What is the price of BNTX shares?

As of October 28, 2025, the stock is trading at USD 106.05 with a total of 341,089 shares traded.
Over the past week, the price has changed by -1.76%, over one month by +8.10%, over three months by -5.98% and over the past year by -6.37%.

Is BioNTech SE a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, BioNTech SE (NASDAQ:BNTX) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 13.78 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BNTX is around 88.76 USD . This means that BNTX is currently overvalued and has a potential downside of -16.3%.

Is BNTX a buy, sell or hold?

BioNTech SE has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy BNTX.

Strong Buy: 13
Buy: 3
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BNTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	134.9	27.2%
Analysts Target Price	134.9	27.2%
ValueRay Target Price	101.4	-4.4%

BNTX Fundamental Data Overview October 16, 2025

Market Cap EUR = 21.19b (24.67b USD * 0.8589 USD.EUR)
P/E Forward = 7.0373
P/S = 8.5698
P/B = 1.157
P/EG = 0.0449
Beta = 1.462
Revenue TTM = 2.88b EUR
EBIT TTM = -485.6m EUR
EBITDA TTM = -227.6m EUR
Long Term Debt = 217.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 52.4m EUR (from shortTermDebt, last quarter)
Debt = 269.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -10.00b EUR (from netDebt column, last quarter)
Enterprise Value = 7.42b EUR (21.19b + Debt 269.6m - CCE 14.04b)
Interest Coverage Ratio = -9.21 (Ebit TTM -485.6m / Interest Expense TTM 52.7m)
FCF Yield = -34.18% (FCF TTM -2.54b / Enterprise Value 7.42b)
FCF Margin = -88.12% (FCF TTM -2.54b / Revenue TTM 2.88b)
Net Margin = -12.07% (Net Income TTM -347.4m / Revenue TTM 2.88b)
Gross Margin = 79.84% ((Revenue TTM 2.88b - Cost of Revenue TTM 580.2m) / Revenue TTM)
Gross Margin QoQ = 70.71% (prev 54.16%)
Tobins Q-Ratio = 0.34 (Enterprise Value 7.42b / Total Assets 21.64b)
Interest Expense / Debt = 1.26% (Interest Expense 3.40m / Debt 269.6m)
Taxrate = 4.00% (-16.1m / -402.7m)
NOPAT = -466.2m (EBIT -485.6m * (1 - 4.00%)) [loss with tax shield]
Current Ratio = 8.61 (Total Current Assets 15.93b / Total Current Liabilities 1.85b)
Debt / Equity = 0.01 (Debt 269.6m / totalStockholderEquity, last quarter 18.51b)
Debt / EBITDA = 43.94 (negative EBITDA) (Net Debt -10.00b / EBITDA -227.6m)
Debt / FCF = 3.94 (negative FCF - burning cash) (Net Debt -10.00b / FCF TTM -2.54b)
Total Stockholder Equity = 19.00b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.61% (Net Income -347.4m / Total Assets 21.64b)
RoE = -1.83% (Net Income TTM -347.4m / Total Stockholder Equity 19.00b)
RoCE = -2.53% (EBIT -485.6m / Capital Employed (Equity 19.00b + L.T.Debt 217.2m))
RoIC = -2.42% (negative operating profit) (NOPAT -466.2m / Invested Capital 19.25b)
WACC = 11.27% (E(21.19b)/V(21.46b) * Re(11.40%) + D(269.6m)/V(21.46b) * Rd(1.26%) * (1-Tc(0.04)))
Discount Rate = 11.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.13%
Fair Price DCF = unknown (Cash Flow -2.54b)
EPS Correlation: -53.83 | EPS CAGR: -37.47% | SUE: 0.88 | # QB: 1
Revenue Correlation: -56.29 | Revenue CAGR: -60.95% | SUE: -0.01 | # QB: 0

Additional Sources for BNTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle